|
Evaluation of tumor MET protein expression, MET gene amplification, and HER2 expression in Chinese patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen; Gilead Sciences; Juno Therapeutics; Kite, a Gilead company |
Travel, Accommodations, Expenses - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |